Literature DB >> 28539429

Bolstering the Number and Function of HSV-1-Specific CD8+ Effector Memory T Cells and Tissue-Resident Memory T Cells in Latently Infected Trigeminal Ganglia Reduces Recurrent Ocular Herpes Infection and Disease.

Arif A Khan1, Ruchi Srivastava1, Aziz A Chentoufi1, Elizabeth Kritzer1, Sravya Chilukuri1, Sumit Garg1, David C Yu1, Hawa Vahed1, Lei Huang1, Sabrina A Syed1, Julie N Furness1, Tien T Tran1, Nesburn B Anthony1, Christine E McLaren2, John Sidney3, Alessandro Sette3, Randolph J Noelle4, Lbachir BenMohamed5,6,7.   

Abstract

HSV type 1 (HSV-1) is a prevalent human pathogen that infects >3.72 billion individuals worldwide and can cause potentially blinding recurrent corneal herpetic disease. HSV-1 establishes latency within sensory neurons of trigeminal ganglia (TG), and TG-resident CD8+ T cells play a critical role in preventing its reactivation. The repertoire, phenotype, and function of protective CD8+ T cells are unknown. Bolstering the apparent feeble numbers of CD8+ T cells in TG remains a challenge for immunotherapeutic strategies. In this study, a comprehensive panel of 467 HLA-A*0201-restricted CD8+ T cell epitopes was predicted from the entire HSV-1 genome. CD8+ T cell responses to these genome-wide epitopes were compared in HSV-1-seropositive symptomatic individuals (with a history of numerous episodes of recurrent herpetic disease) and asymptomatic (ASYMP) individuals (who are infected but never experienced any recurrent herpetic disease). Frequent polyfunctional HSV-specific IFN-γ+CD107a/b+CD44highCD62LlowCD8+ effector memory T cells were detected in ASYMP individuals and were primarily directed against three "ASYMP" epitopes. In contrast, symptomatic individuals have more monofunctional CD44highCD62LhighCD8+ central memory T cells. Furthermore, therapeutic immunization with an innovative prime/pull vaccine, based on priming with multiple ASYMP epitopes (prime) and neurotropic TG delivery of the T cell-attracting chemokine CXCL10 (pull), boosted the number and function of CD44highCD62LlowCD8+ effector memory T cells and CD103highCD8+ tissue-resident T cells in TG of latently infected HLA-A*0201-transgenic mice and reduced recurrent ocular herpes following UV-B-induced reactivation. These findings have profound implications in the development of T cell-based immunotherapeutic strategies to treat blinding recurrent herpes infection and disease.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28539429      PMCID: PMC5515716          DOI: 10.4049/jimmunol.1700145

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

1.  Identification of CTL epitopes in hepatitis C virus by a genome-wide computational scanning and a rational design of peptide vaccine.

Authors:  Toshie Mashiba; Keiko Udaka; Yasuko Hirachi; Yoichi Hiasa; Tomoya Miyakawa; Yoko Satta; Tsutomu Osoda; Sayo Kataoka; Michinori Kohara; Morikazu Onji
Journal:  Immunogenetics       Date:  2007-01-16       Impact factor: 2.846

2.  Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture.

Authors:  John Sidney; Scott Southwood; Carrie Moore; Carla Oseroff; Clemencia Pinilla; Howard M Grey; Alessandro Sette
Journal:  Curr Protoc Immunol       Date:  2013-02

3.  Efficacy results of a trial of a herpes simplex vaccine.

Authors:  Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

4.  A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group.

Authors:  A G Langenberg; L Corey; R L Ashley; W P Leong; S E Straus
Journal:  N Engl J Med       Date:  1999-11-04       Impact factor: 91.245

Review 5.  Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system.

Authors:  Anthony B Nesburn; Ilham Bettahi; Xiuli Zhang; Xiaoming Zhu; Winston Chamberlain; Rasha E Afifi; Steven L Wechsler; Lbachir BenMohamed
Journal:  Ocul Surf       Date:  2006-10       Impact factor: 5.033

6.  Homing in on the cellular immune response to HSV-2 in humans.

Authors:  David M Koelle; Julio C Gonzalez; Andrew S Johnson
Journal:  Am J Reprod Immunol       Date:  2005-04       Impact factor: 3.886

7.  Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88.

Authors:  Xiuli Zhang; Xavier Dervillez; Aziz Alami Chentoufi; Tina Badakhshan; Ilham Bettahi; Lbachir Benmohamed
Journal:  J Immunol       Date:  2012-09-26       Impact factor: 5.422

Review 8.  New concepts in herpes simplex virus vaccine development: notes from the battlefield.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed
Journal:  Expert Rev Vaccines       Date:  2009-08       Impact factor: 5.217

9.  A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge.

Authors:  X Zhang; A A Chentoufi; G Dasgupta; A B Nesburn; M Wu; X Zhu; D Carpenter; S L Wechsler; S You; L BenMohamed
Journal:  Mucosal Immunol       Date:  2008-12-24       Impact factor: 7.313

10.  The role of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus on virus replication and pathogenicity.

Authors:  Kevin R Mott; Aziz A Chentoufi; Dale Carpenter; Lbachir BenMohamed; Steven L Wechsler; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-24       Impact factor: 4.799

View more
  24 in total

1.  Herpes Simplex Virus 1 Replication, Ocular Disease, and Reactivations from Latency Are Restricted Unilaterally after Inoculation of Virus into the Lip.

Authors:  Nolwenn Poccardi; Antoine Rousseau; Oscar Haigh; Julie Takissian; Thierry Naas; Claire Deback; Louise Trouillaud; Mohammad Issa; Simon Roubille; Franceline Juillard; Stacey Efstathiou; Patrick Lomonte; Marc Labetoulle
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

2.  High Frequency of Gamma Interferon-Producing PLZFloRORγtlo Invariant Natural Killer 1 Cells Infiltrating Herpes Simplex Virus 1-Infected Corneas Is Associated with Asymptomatic Ocular Herpesvirus Infection.

Authors:  Nisha R Dhanushkodi; Ruchi Srivastava; Swayam Prakash; Soumyabrata Roy; Pierre-Gregoire A Coulon; Hawa Vahed; Angela M Nguyen; Stephanie Salazar; Lan Nguyen; Cassandra Amezquita; Caitlin Ye; Vivianna Nguyen; Lbachir BenMohamed
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

Review 3.  Pathogenesis of herpes simplex keratitis: The host cell response and ocular surface sequelae to infection and inflammation.

Authors:  Ann-Marie Lobo; Alex M Agelidis; Deepak Shukla
Journal:  Ocul Surf       Date:  2018-10-11       Impact factor: 5.033

4.  Distinguishing Features of High- and Low-Dose Vaccine against Ocular HSV-1 Infection Correlates with Recognition of Specific HSV-1-Encoded Proteins.

Authors:  Daniel J J Carr; Grzegorz B Gmyrek; Adrian Filiberti; Amanda N Berube; William P Browne; Brett M Gudgel; Virginie H Sjoelund
Journal:  Immunohorizons       Date:  2020-10-09

5.  CXCL17 Chemokine-Dependent Mobilization of CXCR8+CD8+ Effector Memory and Tissue-Resident Memory T Cells in the Vaginal Mucosa Is Associated with Protection against Genital Herpes.

Authors:  Ruchi Srivastava; Marcela Hernández-Ruiz; Arif A Khan; Mona A Fouladi; Grace J Kim; Vincent T Ly; Taikun Yamada; Cynthia Lam; Sheilouise A B Sarain; Undariya Boldbaatar; Albert Zlotnik; Elmostafa Bahraoui; Lbachir BenMohamed
Journal:  J Immunol       Date:  2018-03-16       Impact factor: 5.422

6.  Unique Type I Interferon, Expansion/Survival Cytokines, and JAK/STAT Gene Signatures of Multifunctional Herpes Simplex Virus-Specific Effector Memory CD8+ TEM Cells Are Associated with Asymptomatic Herpes in Humans.

Authors:  Hawa Vahed; Anshu Agrawal; Ruchi Srivastava; Swayam Prakash; Pierre-Gregoire A Coulon; Soumyabrata Roy; Lbachir BenMohamed
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

7.  Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107+ CD8+ T Cells That Infiltrate the Corneas and Trigeminal Ganglia of Humanized HLA Transgenic Rabbits and Protect against Ocular Herpes Challenge.

Authors:  Arif A Khan; Ruchi Srivastava; Hawa Vahed; Soumyabrata Roy; Sager S Walia; Grace J Kim; Mona A Fouladi; Taikun Yamada; Vincent T Ly; Cynthia Lam; Anthony Lou; Vivianna Nguyen; Undariya Boldbaatar; Roger Geertsema; Nigel W Fraser; Lbachir BenMohamed
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

8.  Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.

Authors:  Grzegorz B Gmyrek; Adrian Filiberti; Micaela Montgomery; Alisha Chitrakar; Derek J Royer; Daniel J J Carr
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

9.  Herpes Labialis, Chlamydophila pneumoniae, Helicobacter pylori, and Cytomegalovirus Infections and Risk of Dementia: The Framingham Heart Study.

Authors:  Eduardo Marques Zilli; Adrienne O'Donnell; Joel Salinas; Hugo J Aparicio; Mitzi Michelle Gonzales; Mini Jacob; Alexa Beiser; Sudha Seshadri
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

10.  Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8+ TRM Cells and Reduces Ocular Herpes Simplex Infection and Disease in HLA Transgenic Rabbits.

Authors:  Soumyabrata Roy; Pierre-Gregoire Coulon; Swayam Prakash; Ruchi Srivastava; Roger Geertsema; Nisha Dhanushkodi; Cynthia Lam; Vivianna Nguyen; Elyssa Gorospe; Angela M Nguyen; Stephanie Salazar; Nuha I Alomari; Wasay R Warsi; Lbachir BenMohamed
Journal:  J Virol       Date:  2019-08-28       Impact factor: 6.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.